Västra Hamnen Möter

Västra Hamnen Möter - Precise Biometrics

Västra Hamnen Möter - Safeture

Västra Hamnen Möter - Nexam Chemical Holding

Västra Hamnen Möter - Shape Robotics

Västra Hamnen Möter - Clemondo Group

Västra Hamnen Möter - BPC Instruments

Västra Hamnen Möter - OptiCept Technologies

Västra Hamnen Möter - Neola Medical

Västra Hamnen Möter - Arrow Lake

Västra Hamnen Möter - Spago Nanomedical

Västra Hamnen Möter - Nasdaq

Västra Hamnen Möter - SenzaGen

Västra Hamnen Möter - Advenica

Västra Hamnen Möter - Xintela

InCoax Networks

CDON

Malmö stad

Transactions

Sydsvenska Hem

Qgroup

BIMobject

Transaktioner

Ongoing transactions

Videos

Articles of association

Pågående erbjudanden

Bolagsordning

ProstaLund

Bolagsstämmor

ProstaLund: Hack i kurvan eller bestående trend?

ProstaLund: Från utmaning till möjlighet

General meetings

ProstaLund: CoreTherm Eagle flygfärdig

ProstaLund: Nytt ledarskap efter turbulent höst

Home

Completed transactions

Slutförda uppdrag

Financial reports

Board of Directors

Styrelse

Finansiella rapporter

Analyser

Research updates

ProstaLund presenterar Q4 2022

ProstaLund presenterar på Investerardagen 2 december 2021

Movinn presenterar Q1 2023

ProstaLund presenterar Q1 2022

BeammWave

Chordate presenterar på Investerardagen 2 december 2022

Chordate Medical presenterar Q4 2022

ProstaLund presents Q4 2022

Chordate Medical presents Q4 2022

Ledning

ProstaLund presenterar Q3 2021

ProstaLund presenterar Q4 2021

aXichem presenterar Q2 2023

Bioextrax

ProstaLund presents Q2 2022

Qgroup presenterar på Investerardagen 9 juni 2022

Qlife presenterar på Investerardagen 2 december 2021

RugVista presenterar på Investerardagen 2 december 2021

Iconovo

SenzaGen presenterar på Investerardagen 2 december 2021

Medimi presenterar Q1 2024

Speqta presenterar på Investerardagen 9 juni 2022

Movinn presenterar Q2 2023

Chordate Medical presenterar Q2 2023

Chordate Medical presents Q2 2023

USWE presenterar på Investerardagen 8 juni 2021

USWE presenterar Q2 2021/22

Movinn presents Q2 2023

USWE presenterar Q3 2021/22

Crunchfish presents Q2 2023

Chordate Medical presenterar Q1 2023

Chordate Medical presents Q1 2023

USWE presenterar Q4 2021/22

USWE presents Q1 2022/23

CombiGene

Bioextrax kommenterar Q2 2024

Crunchfish presenterar Q2 2023

Medimi presenterar Q2 2023

Crunchfish presents Q1 2023

Crunchfish presenterar Q1 2023

Medimi presenterar Q1 2023

Crunchfish presents Q3 2023

Medimi presents Q1 2023

USWE Sports presenterar på Investerardagen 9 juni 2022

Lime Technologies

Certified Adviser

ViroGates presenterar Q1 2022

Medimi presents Q2 2023

Cantargia

ViroGates presenterar Q2 2021

ViroGates presenterar Q3 2021

ViroGates presenterar Q4 2021

Medimi presents Q2 2024

Medimi's CEO on the acquisition of MedThings

Services

About us

Contact

Here is more information about Västra Hamnen Corporate Finance's services.

Here you will find information about Västra Hamnen Corporate Finance's ongoing and completed transactions.

Here you will find more information about Västra Hamnen Corporate Finance.

Here, Västra Hamnen Corporate Finance's information for investors is gathered.

Investor relations

Västra Hamnen Corporate Finance

Xintela's main owner Flerie, has committed to exercise all its TO3 warrants in the ongoing subscription, adding MSEK 28 to Xintela. Flerie also provided a bridge loan of MSEK 9 to be repaid in December. With short-term funding secured, Xintela can focus on its projects. The recruitment of patients in the venous leg ulcer study advances and an interim report from the osteoarthritis study is expected by the end of Q1 2025. In parallel,  the company is setting up the GMP process with Region Östergötland. This is Xintela's first commercial agreement as a provider of advanced therapy medical products. Investors are also awaiting updates on the process with EQGen Biomedicals regarding EQSTEM. 

Xintela: Flerie provides short-term funding

Xintela recently extended the follow-up of the patients in the highest dose level group by six months in its OA study. The company expects an interim analysis from the 18-month follow-up in Q1 2025. Region Östergötland has assigned Xintela to develop and establish a GMP process for autologous skin cells for the treatment of burns. The deal is worth MSEK 3.6. Awaiting the license deal with EQGen Biomedical to materialise, we keep the fair value at SEK 1.30 per share.

Xintela: Activities below the surface

In connection with the Q1 report, Xintela announced a signed term sheet with the US firm EQGen Biomedical regarding EQSTEM, Xintela’s veterinarian joint disease treatment. We expect details to be disclosed once EQGen Biomedical secures funding and the parties announce a license agreement.

Xintela: Closing in on the first license agreement

During Q4 2023, Xintela's project progressed according to plan. To meet the short-term capital requirement, the company raised a loan of SEK 16.5 million from Flerie Invest, Xintela's main owner. 

Xintela: Awaiting results in trials and discussions

Xintela is a biopharma company with two assets in clinical development phase. The company focuses on stem cell therapy and cancer therapy based on the cell surface receptor integrin α10β1.

Xintela’s integrin marker carries hidden value

Martin Dominique

Tobias Karlsson

Xintela

Xintela

Analyst

Martin Dominique

Tobias Karlsson

Initial analysis

Xintela’s integrin marker carries hidden value

Research updates

Related Videos